BioSpace News Archive

Avantor, Inc. announced that its Board of Directors has declared a quarterly cash dividend to holders of its 6.250% Series A Mandatory Convertible Preferred Stock of $0.78 per share at a rate per share of 1.560%, payable on May 17, 2021 to holders of record on April 1, 2021.

AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.

Movano Inc . (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health to help prevent and better manage chronic diseases, today announced that it will report first quarter 2021 financial and operating results on Thursday, May 13, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 2:00 p.m. PDT (5:00 p.m. EDT).

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, announced that it has filed and obtained a receipt for a final base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Wednesday, May 5, 2021.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million

Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, today announced that it will report financial results for the first quarter 2021 after the market close on Wednesday, May 5, 2021.

NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17.00 per share